GoKawiilCompeting interests
E.A.A. is a founder of Personalis, Deepcell, Svexa, Saturnus Bio and Swift Bio; an advisor to Pacific Biosciences; and a non-executive director of AstraZeneca and Dexcom. N.J.L. is an advisor to Everygene Collaborative, and has received support in kind from Illumina, Pacific Biosciences and Ultima. B.R.R. is an advisor to Autonomous Therapeutics and GC Therapeutics. B.P. is a consultant to Calico Life Sciences and Bimodal, and an advisor to the California Institute for Regenerative Medicine. F.J.S. has received research support from Illumina, PacBio and Oxford Nanopore. K.K. is a scientific advisor to CareDx and Eledon Pharmaceuticals. A.M. is a cofounder of Site Therapeutics, Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics; serves on the boards of directors at Site Therapeutics, Spotlight Therapeutics and Survey Genomics; is a member of the scientific advisory boards of Site Therapeutics, Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen and Tenaya; owns stock in Arsenal Biosciences, Site Therapeutics, Spotlight Therapeutics, NewLimit, Survey Genomics, Tenaya and Lightcast; has received fees from Site Therapeutics, Arsenal Biosciences, Spotlight Therapeutics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, Trizell, Vertex, Merck, Amgen, Genentech, GLG, ClearView Healthcare, AlphaSights, Rupert Case Management, Bernstein and ALDA; and is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The laboratory of A.M. has received research support from the Parker Institute for Cancer Immunotherapy, the Emerson Collective, Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem, and reagents from Genscript and Illumina. L.M.S. is a founder of Sophia Genetics, LevitasBio and Recombia Biosciences, and has received collaborative support from Novartis and Dewpoint Therapeutics. H.L.R. has received research support from Microsoft, and is a consultant for Quest Diagnostics. R.M.C. is a partner and vice chair at Sixth Street Partners; a board member of Alphabet, the Broad Institute of MIT and Harvard, and Datavant; and a former board or advisory board member of Cambrian Biopharma, Earli, Recursion Pharmaceuticals and Sema4. A.S.B. is a scientific founder and serves on the scientific advisory board and board of directors at Stylus Medicine; has a patent filed (serine recombinases); serves on the scientific advisory boards of Cantata and Caribou Biosciences; and is a paid consultant of BiomX and SNIPR Biome. M.H.P. serves on the scientific advisory boards of Allogene Therapeutics, Dispatch Bio and Orthobio; is a founder of Kamau Therapeutics; and has equity in CRISPR Therapeutics and Lenz Therapeutics. A.A.A. reports consulting for and having stock options in CiberMed; has received consulting fees and research funding from Celgene, Adaptive Biotechnologies and Capstan Therapeutics; holds stock options in CAPP Medical; has received consulting fees, honoraria and travel funding from Roche; holds stock options in Forty Seven and CARGO Therapeutics; has received consulting fees and travel from Gilead; has received consulting fees from and holds stock options in Foresight Diagnostics; has received honoraria from Janssen; and consults for the Lymphoma Research Foundation. P.G. is a cofounder and director at Need, and is a paid consultant for ResearchDx and Endeavour Enterprises. V.A.S. was supported by the National Center for Biotechnology Information of the National Library of Medicine, National Institutes of Health. A.C. is an employee of Google and receives stock as part of a standard compensation package. The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a cofounder of Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Evercrisp, Scribe Therapeutics and Mammoth Biosciences; is a scientific advisory board member at Evercrisp, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, the Column Group and Inari; is an advisor for Aditum Bio; is chief science advisor to Sixth Street; is a director at Johnson & Johnson, Altos and Tempus; and has a research project sponsored by Apple Tree Partners. L.B.M. has received and/or will be receiving compensation (cash and/or stock-related) for serving on the board of directors of Atrio Health Plans, Biogen and Caris Life Sciences, as well as for advisory activities with aMoon, General Atlantic, Goldman Sachs and Mammoth Biosciences. F.D.U. holds equity in and is a paid advisor to Tune Therapeutics and Cimeio Therapeutics; is a paid consultant to Vertex Pharmaceuticals and Ionis Pharmaceuticals; and receives salary and research support from Danaher Corporation. The remaining authors declare no competing interests.